Lantheus makes pharma veteran Jeffrey Bailey CEO
This article was originally published in Clinica
Imaging agent specialist Lantheus Medical Imaging has appointed Jeffrey Bailey as its president and CEO, succeeding Donald Kiepert, who has resigned "to pursue other opportunities" after leading the firm for five years. Mr Bailey was previously chief operating officer of Fougera Pharmaceuticals, a position he held since 2011. Before this, he was COO of King Pharmaceuticals (from August 2010 until August 2011); general manager at Novartis (2008-2010); and national sales director for Johnson & Johnson (1984-2006) and its Janssen Pharmaceutica division (2004-2006). Lantheus has also named a new chairman, Brian Markison, who has been a board member since September.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.